Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
Open Access
- 16 May 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10), 5533
- https://doi.org/10.3390/ijms23105533
Abstract
Systemic sclerosis (SSc) is characterised by progressive multiple organ fibrosis leading to morbidity and mortality. Lysyl oxidases play a vital role in the cross-linking of collagens and subsequent build-up of fibrosis in the extracellular matrix. As such, their inhibition provides a novel treatment paradigm for SSc. A novel small molecule pan-lysyl oxidase inhibitor, PXS-5505, currently in clinical development for myelofibrosis treatment was evaluated using in vivo rodent models resembling the fibrotic conditions in SSc. Both lysyl oxidase and lysyl oxidase-like 2 (LOXL2) expression were elevated in the skin and lung of SSc patients. The oral application of PXS-5505 inhibited lysyl oxidase activity in the skin and LOXL2 activity in the lung. PXS-5505 exhibited anti-fibrotic effects in the SSc skin mouse model, reducing dermal thickness and α-smooth muscle actin. Similarly, in the bleomycin-induced mouse lung model, PXS-5505 reduced pulmonary fibrosis toward normal levels, mediated by its ability to normalise collagen/elastin crosslink formation. PXS-5505 also reduced fibrotic extent in models of the ischaemia-reperfusion heart, the unilateral ureteral obstruction kidney, and the CCl4-induced fibrotic liver. PXS-5505 consistently demonstrates potent anti-fibrotic efficacy in multiple models of organ fibrosis relevant to the pathogenesis of SSc, suggesting that it may be efficacious as a novel approach for treating SSc.This publication has 52 references indexed in Scilit:
- Activated protein C improves left ventricular remodelling after ischemia–reperfusion injury in ratsInternational Journal of Cardiology, 2012
- Animal models of systemic sclerosis: Prospects and limitationsArthritis & Rheumatism, 2010
- Standardized quantification of pulmonary fibrosis in histological samplesBioTechniques, 2008
- Lysyl oxidase in development, aging and pathologies of the skinPathologie Biologie, 2005
- D-penicillamine is not an effective treatment in systemic sclerosisScandinavian Journal of Rheumatology, 2001
- D-penicillamine in systemic sclerosis? Yes!Scandinavian Journal of Rheumatology, 2001
- Infarct scar: a dynamic tissueCardiovascular Research, 2000
- Increased expression of lysyl oxidase in skin with sclerodermaBritish Journal of Dermatology, 1995
- Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage.Journal of the American College of Cardiology, 1987
- Pharmacologic Control of Surface Scarring in Human BeingsAnnals of Surgery, 1981